These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 11429663

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The Dutch guidelines for treatment with infliximab for Crohn's disease.
    Vermeire S.
    Neth J Med; 2006; 64(7):210-1. PubMed ID: 16929081
    [No Abstract] [Full Text] [Related]

  • 3. Infliximab is the drug we have been waiting for in Crohn's disease.
    Rutgeerts P.
    Inflamm Bowel Dis; 2000 May; 6(2):132-6. PubMed ID: 10833073
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize.
    Sandborn WJ.
    Gastroenterology; 2003 Apr; 124(4):1140-5. PubMed ID: 12671907
    [No Abstract] [Full Text] [Related]

  • 6. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR.
    Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract] [Full Text] [Related]

  • 7. Infliximab in Crohn's disease.
    Rodrigo Saéz L.
    Rev Esp Enferm Dig; 2004 Jun; 96(6):359-63; 364-8. PubMed ID: 15230665
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Infliximab: how to use it in pediatric Crohn's disease.
    Ruemmele FM.
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):12-4. PubMed ID: 15187774
    [No Abstract] [Full Text] [Related]

  • 10. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J, Kucharzik T.
    Z Gastroenterol; 2005 Jul 13; 43(7):689-90. PubMed ID: 16001352
    [No Abstract] [Full Text] [Related]

  • 13. A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies.
    Takahashi K, Fujimoto T, Shioya M, Nishida A, Bamba S, Inatomi O, Imaeda H, Kitoh K, Andoh A.
    Clin J Gastroenterol; 2015 Apr 13; 8(2):88-91. PubMed ID: 25795267
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab for severe peripheral ulcerative keratopathy revealing Crohn's disease.
    Angioi K, Kaminsky P, Peyrin-Biroulet L.
    Inflamm Bowel Dis; 2011 Mar 13; 17(3):866-7. PubMed ID: 20848541
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.